Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) EBT Margin (2016 - 2025)

Historic EBT Margin for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to 2.46%.

  • Immucell's EBT Margin rose 91900.0% to 2.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.42%, marking a year-over-year increase of 281600.0%. This contributed to the annual value of 8.1% for FY2024, which is 249200.0% up from last year.
  • Immucell's EBT Margin amounted to 2.46% in Q3 2025, which was up 91900.0% from 7.82% recorded in Q2 2025.
  • In the past 5 years, Immucell's EBT Margin ranged from a high of 17.96% in Q1 2025 and a low of 67.13% during Q1 2023
  • Moreover, its 5-year median value for EBT Margin was 8.38% (2024), whereas its average is 11.4%.
  • Per our database at Business Quant, Immucell's EBT Margin plummeted by -757000bps in 2023 and then soared by 611100bps in 2024.
  • Quarter analysis of 5 years shows Immucell's EBT Margin stood at 1.38% in 2021, then crashed by -3182bps to 42.61% in 2022, then soared by 59bps to 17.41% in 2023, then soared by 139bps to 6.72% in 2024, then plummeted by -137bps to 2.46% in 2025.
  • Its EBT Margin stands at 2.46% for Q3 2025, versus 7.82% for Q2 2025 and 17.96% for Q1 2025.